Aminex Therapeutics, Inc.

Aminex Therapeutics, Inc. is a drug development company focused on advancing a novel immunotherapy for the treatment of cancer. Based in Kirkland, Washington, in the United States, the company describes itself as pursuing an immuno-oncology approach built on polyamine depletion therapy. Polyamines are molecules found in high concentrations in cancer cells and the tumor microenvironment and are linked to immune system suppression. Aminex's approach aims to significantly reduce both the uptake and the production of polyamines, which in turn reduces myeloid-derived suppressor cells in the tumor microenvironment and allows activation of the innate immune system to attack solid tumors. The company's lead drug candidate is AMXT 1501 + DFMO, an oral, small molecule therapy. It combines AMXT 1501, Aminex's patented polyamine uptake inhibitor, with DiFluoroMethylOrnithine (DFMO, eflornithine), an off-patent polyamine synthesis inhibitor. According to the company, the two agents work in conjunction to provide a synergistic immune system therapy applicable to a majority of solid tumor cancers. Aminex states that it has advanced AMXT 1501 + DFMO through target discovery, patenting, pre-clinical research and now into clinical development for the potential benefit of cancer patients, and that a Phase 1b/2 clinical trial is now enrolling. Aminex Therapeutics is led by an experienced management team and board of directors. David Meek serves as Director and Executive Chairman; he brings over 30 years of experience in the biopharmaceutical industry, including service as Chief Executive Officer and a board member of Mirati Therapeutics, CEO and board member of FerGene, and CEO and board member of Ipsen. The company reports that it has received backing of approximately $39 million since inception from a group of private investors, indicating that it is a privately held, investor-backed enterprise rather than a publicly listed company. Its activities center on the United States, where its headquarters and clinical development efforts are based.

Aminex Therapeutics, Inc. is a drug development company focused on advancing a novel immunotherapy for the treatment of cancer. The company is based in Kirkland, Washington, in the United States. Its scientific foundation rests on polyamine depletion therapy: an immuno-oncology approach that seeks to significantly reduce the uptake and production of polyamines, molecules found in high concentrations in cancer cells and the tumor microenvironment and linked to immune system suppression. By reducing both sources of polyamines and, in turn, myeloid-derived suppressor cells in the tumor microenvironment, the approach is designed to allow activation of the innate immune system to attack solid tumors. According to the company, it has advanced its lead drug candidate, AMXT 1501 + DFMO, through target discovery, patenting, pre-clinical research and now into clinical development for the potential benefit of cancer patients. AMXT 1501 + DFMO is an oral, small molecule therapy composed of AMXT 1501, the company's patented polyamine uptake inhibitor, and DiFluoroMethylOrnithine (DFMO, eflornithine), an off-patent polyamine synthesis inhibitor. The two agents are intended to work in conjunction to provide a synergistic immune system therapy applicable to a majority of solid tumor cancers. The company has announced that a Phase 1b/2 clinical trial is now enrolling, and it has published commentary describing how a new direction in oncology emerged from years of polyamine research. Aminex Therapeutics is led by an experienced management team and board of directors. David Meek serves as Director and Executive Chairman; he brings over 30 years of experience in the biopharmaceutical industry, having held key leadership positions across a range of publicly traded and private biotech companies. His prior roles include Chief Executive Officer and board member at Mirati Therapeutics, CEO and board member of FerGene, and CEO and board member of Ipsen, as well as executive positions at Baxalta, Endocyte, Novartis and Johnson & Johnson. The company reports that it has received backing of approximately $39 million since inception from a passionate, committed group of private investors, which indicates that it is a privately held, investor-backed enterprise. Its activities are centered on the United States, where its headquarters and clinical development efforts are based.

• Aminex Therapeutics advances AMXT 1501 + DFMO through target discovery, patenting and pre-clinical research into clinical development.

  [2]About – Aminexaminextx.com
• Phase 1b/2 clinical trial of AMXT 1501 + DFMO is now enrolling.

  [1]Aminex – Empowering the Immune System Against Canceraminextx.com
• Company reports approximately $39 million in backing since inception from private investors.

  [2]About – Aminexaminextx.com

Clinical-stage immuno-oncology drug developer focused on polyamine depletion therapy for solid tumors.

• AMXT 1501 + DFMO

  An oral, small molecule immuno-oncology drug candidate composed of AMXT 1501, a patented polyamine uptake inhibitor, and DiFluoroMethylOrnithine (DFMO, eflornithine), an off-patent polyamine synthesis inhibitor. The combination is designed to provide a synergistic immune system therapy applicable to a majority of solid tumor cancers.

1. 1Aminex – Empowering the Immune System Against Canceraminextx.com
2. 2About – Aminexaminextx.com
3. 3Board – Aminexaminextx.com
4. 4Management – Aminexaminextx.com
5. 5Aminex Therapeutics (United States) – Wikidatawikidata.org